PUBLISHER: The Business Research Company | PRODUCT CODE: 1957579
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957579
Parathyroid hormone is a substance secreted by the parathyroid gland that helps regulate the storage and use of calcium in the body. Elevated levels of parathyroid hormone can lead to increased blood calcium levels and may indicate the presence of a disease. It is also referred to as PTH, parathyrin, and parathormone.
The primary product types in the parathyroid hormone category include recombinant parathyroid hormone and parathyroid hormone analogs. Recombinant parathyroid hormone, which imitates the action of natural parathyroid hormone, is utilized in the treatment of osteoporosis. The various conditions addressed include hypocalcemia and hypoparathyroidism, and these products are used across multiple settings such as hospitals, clinics, and others.
Tariffs have impacted the parathyroid hormone market by increasing the cost of imported recombinant hormones, analogues, and related medical devices. Hospital and clinic segments in regions like North America and Europe, which depend on imports, are most affected. This has led to higher treatment costs and supply chain challenges. However, tariffs have also promoted local manufacturing, encouraged innovation in hormone therapies, and supported the development of cost-optimized solutions.
The parathyroid hormone market research report is one of a series of new reports from The Business Research Company that provides parathyroid hormone market statistics, including parathyroid hormone industry global market size, regional shares, competitors with a parathyroid hormone market share, detailed parathyroid hormone market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid hormone industry. This parathyroid hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The parathyroid hormone market size has grown rapidly in recent years. It will grow from $2.51 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to limited availability of recombinant parathyroid hormone, low disease awareness among patients, reliance on conventional vitamin d therapy, growing hospital and clinic infrastructure, increasing post-surgical parathyroid complications.
The parathyroid hormone market size is expected to see rapid growth in the next few years. It will grow to $4.4 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to development of advanced parathyroid hormone analogues, rising adoption of personalized medicine approaches, expansion of hospital and specialty clinics, integration of digital patient monitoring tools, increasing government and healthcare initiatives for hypocalcemia and hypoparathyroidism. Major trends in the forecast period include rising incidence of hypocalcemia and hypoparathyroidism, increasing use of recombinant parathyroid hormone therapies, growth in parathyroid hormone analogues for personalized treatment, expansion of hospital and clinic-based parathyroid care programs, focus on post-surgical management and vitamin d supplementation.
The growing geriatric population is expected to drive the expansion of the parathyroid hormone market in the coming years. The geriatric population includes older adults, generally aged 65 years and above, who often face age-related health conditions and require specialized medical care and support. This demographic trend is largely the result of longer life expectancy, improvements in healthcare, and declining birth rates, which together have increased the proportion of elderly individuals worldwide. Parathyroid hormone plays an important role for older adults by regulating calcium balance and bone metabolism, thereby helping reduce the risk of osteoporosis and fractures, conditions commonly seen in the aging population. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Additionally, this age group's share of the total population is expected to grow from 17% to 23% over the same period. As a result, the expanding geriatric population is contributing significantly to the growth of the parathyroid hormone market.
Leading companies in the parathyroid hormone market are concentrating on the development of biosimilars of parathyroid-based therapies, including prodrugs of parathyroid hormone (PTH), to improve treatment availability and effectiveness. A parathyroid hormone prodrug is an inactive substance that converts into active PTH after administration, allowing for sustained release and consistent therapeutic effects to support calcium regulation and bone health. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, announced that the Food & Drug Administration (FDA) had approved YORVIPATH (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults. This once-daily prodrug provides continuous PTH exposure and is designed to benefit approximately 70,000 to 90,000 patients in the United States. The manufacturer, Ascendis Pharma, also offers patient support through its Ascendis Signature Access Program (A.S.A.P.), although patients are required to regularly monitor serum calcium levels to manage the risk of hypercalcemia or hypocalcemia.
In November 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, entered into a strategic partnership with Teijin Limited in Japan to support the development and commercialization of innovative therapies. This collaboration is intended to broaden access to Ascendis Pharma's pipeline products, improve patient care in Japan, and promote innovation and growth within the rare disease and endocrine therapeutics market. Teijin Limited is a Japan-based healthcare and pharmaceutical company dedicated to providing advanced therapies and solutions to address unmet medical needs.
Major companies operating in the parathyroid hormone market are Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited
North America was the largest region in the parathyroid hormone market in 2025. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The parathyroid hormone market consists of sales of parathormone and calcitonin. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Parathyroid Hormone Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses parathyroid hormone market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for parathyroid hormone ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The parathyroid hormone market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.